This Week in BMC Cancer | GenomeWeb

This Week in BMC Cancer

Premium

In BMC Cancer this week, researchers in China and the US examine the association of proteasome activator REGgamma and multiple oncogenic pathways in four human cancers. The team found over-expression of REGgamma in each of those cancers. "We verified elevated REGgamma gene expression in the four types of cancers and identified genes significantly correlated with REGgamma expression, including genes in p53, Myc pathways, and multiple other cancer-related pathways," the authors write.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.